Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ATOS
ATOSSA THERAPEUTICS, INC.
NASDAQ
$2.57
▼ DOWN 0.39% (-0.01)

KEY STATISTICS

Market Cap$25.74 M
52w High$19.35
52w Low$1.70
Dividend Yield—
Frequency—
P/E-0.60
Volume7.03K
Shares Out.9.97M

COMPANY

LEADERSHIP

Steven C. Quay
CHIEF EXECUTIVE
Steven C. Quay

COMPENSATION 2026

Salary$520,000
Stock Awards$0
Incentive Plan Pay$260,000
All Other Comp.$12,000
Total$1,019,736

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 8, 2012
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
16

PRICE TARGET

Target High$75.00
Target Low$10.00
Target Median$42.50
Target Consensus$42.50

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2026-02-02Reverse1:15
2018-04-20Reverse1:12
2016-08-26Reverse1:15

PRICE

$2.57 ▼ DOWN 0.39% (−$0.01)
OVERLAYS
$2.53$2.55$2.589:30 AM9:42 AM9:54 AM10:07 AM10:19 AM10:31 AM10:43 AM2.57

About Atossa Therapeutics, Inc.

https://www.atossatherapeutics.com ↗

Atossa Therapeutics, Inc., a Seattle-based clinical-stage biopharmaceutical company founded in 2008, develops treatments for women's cancers, including Phase II oral (Z)-endoxifen for breast cancer, and explores immunotherapy programs.

INDUSTRY

Biotechnology

A PRODUCT ATOSSA THERAPEUTICS, INC. IS KNOWN FOR

(Z)-endoxifen
(Z)-endoxifen

Atossa's lead clinical-stage oral drug is a potent SERM/D developed to treat and prevent breast cancer and other conditions like Duchenne Muscular Dystrophy.

COMPETITORS

COMPETITOR
ARVN COMPARE
CELC COMPARE
OLMA COMPARE
PBYI COMPARE
RLAY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 256.1K
IWC
0.01% · 29.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
91
TOP 12 OF 91 · RANKED BY POSITION SIZE
Blackrock Inc.
9.2M sh · $10.94M
Vanguard Group Inc
6.1M sh · $3.63M
Ameriprise Financial Inc
3.8M sh · $2.24M
Renaissance Technologies LLC
2.1M sh · $1.22M
Blackrock, Inc.
2.0M sh · $1.18M
Millennium Management LLC
1.7M sh · $1.45M
Geode Capital Management, LLC
1.4M sh · $809.62K
Jacobs Levy Equity Management, Inc
1.0M sh · $618.49K
Citadel Advisors LLC
648.1K sh · $382.39K
State Street Corp
596.5K sh · $351.93K
Susquehanna International Group, Llp
582.6K sh · $343.73K
Ubs Group AG
390.0K sh · $230.1K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Roger W. Marshall
Roger W. Marshall
Purchase
2017-10-25

INSIDER TRADES

★
DIRECTOR
Galli Stephen J
Purchase · 10.0K shares
2026-05-12
★
DIRECTOR
Cigler Tessa
Purchase · 10.0K shares
2026-05-12
★
DIRECTOR
Steinhart Richard I
Purchase · 10.0K shares
2026-05-12
★
DIRECTOR
Finn Jonathan
Purchase · 10.0K shares
2026-05-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
Ascendiant Capital BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
IMMX$13.94COMPARE
WHWK$4.62COMPARE
GLSI$15.67COMPARE
SRZN$22.42COMPARE
COYA$4.59COMPARE
CGTX$1.02COMPARE
ONCY$0.86COMPARE
CLNN$4.23COMPARE